Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid

• Published in: Frontiers in immunology Vol. 12; p. 738907
• Main Authors: Zhang, Yihua, Xu, Qiuyun, Chen, Lihong, Chen, Jiawen, Zhang, Jing, Zou, Ying, Gong, Ting, Ji, Chao
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 14-10-2021
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Azathioprine - therapeutic use; bullous pemphigoid; corticosteroid-spare; Drug Tapering; Drug Therapy, Combination; dupilumab; Female; Humans; IL-4/IL-13; Immunology; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Male; Methylprednisolone - therapeutic use; Middle Aged; Pemphigoid, Bullous - diagnosis; Pemphigoid, Bullous - drug therapy; Pemphigoid, Bullous - immunology; pruritus; Remission Induction; Retrospective Studies; Severity of Illness Index; Skin - drug effects; Skin - immunology; Skin - pathology; Time Factors; Treatment Outcome; Young Adult; pruritus; IL-4/IL-13; bullous pemphigoid; corticosteroid-spare; dupilumab
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2021.738907

Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are often limited by their side effects. Safer treatment modalities are therefore needed. Dupilumab is a biologic agent used to treat BP in recent years.
Medical records of patients with moderate-to-severe BP were retrospectively reviewed. Twenty-four patients were included (follow-up period: 32 weeks), eight of whom received dupilumab in combination with methylprednisolone and azathioprine (dupilumab group) while the other 16 patients received methylprednisolone and azathioprine (conventional group). Response to dupilumab was evaluated by comparison of several parameters (time to stop new blister formation, time to reduce the systemic glucocorticoids to minimal dose, and total amount of methylprednisolone).
The median age of patients in the dupilumab and conventional groups were 64.50 years (range: 22-90 years) and 64.50 years (range: 17-86 years), respectively. The median duration of disease before admission in the dupilumab group was 2 months (range: 1-240 months) and 2.5 months (range: 1-60 months) in the conventional group. The median time to stop new blister formation was 8 days (range: 1-13 days) and 12 days (range: 5-21 days) in patients of the dupilumab and conventional groups, respectively (
 = 0.028 by Kaplan-Meier analysis). In addition, the median time to reduce the systemic glucocorticoids to minimal dose (methylprednisolone 0.08 mg/kg/day) was 121.5 and 148.5 days for the dupilumab and conventional therapy groups, respectively (
 = 0.0053 by Kaplan-Meier analysis). The median total amount of methylprednisolone (at the time of reaching the minimal dose) used in the dupilumab group was 1,898 mg (range: 1,624-2,932 mg) while the cumulative dose of conventional group was 2,344 mg (range: 1,708-4,744 mg) (
 = 0.036 by Mann-Whitney
test). The median total amount of azathioprine (at the time of reaching the minimal dose) used in dupilumab group was 8,300 mg (range: 7,100-10,400 mg) while the total dose of conventional group was 10,300 mg (range: 8,900-14,400 mg) (
 = 0.0048 by Mann-Whitney
test). No adverse event related to dupilumab was recorded.
Dupilumab in addition to methylprednisolone and azathioprine seems superior to methylprednisolone/azathioprine alone in controlling disease progression and accelerating the tapering of glucocorticoids.